|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CO-ADMINISTRATION HAS RESULTED IN BLEEDING AND/OR INCREASED PROTHROMBIN TIME IN FEW PATIENTS
|
PHENYTOIN SERUM LEVELS ARE INCREASED BY THE DRUG
|
INCREASED INCIDENCE OF SIDE EFFECTS ON CO-ADMINISTRATION
|
RENAL CLEARANCE MEASUREMENT CAN NOT BE MADE WITH ACCURACY IN PATIENTS RECEIVING THIS DRUG DUE TO INTERFERENCE WITH CHEMICAL COLOR DEVELOPMENT ESSENTIAL TO ANALYTICAL PROCEDURES
|
CHLOROPROCAIN METABOLITE ( PARA-AMINOBENZOIC ACID) INHIBITS THE ACTION OF SULPHONAMIDES, HENCE SHOULD NOT BE CO-ADMINISTERED
|